Placebo News and Research

RSS

FLUIDDA's breakthrough imaging technology helps optimize COPD treatment

FLUIDDA's breakthrough imaging technology was used to assess the mode of action of Roflumilast, a novel drug to treat patients suffering from chronic obstructive pulmonary disease (COPD).

9 May 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Patients with Parkinson's disease show improvements after exenatide therapy

Follow-Up Study Published in the Journal of Parkinson's Disease Supports an Earlier "Proof of Concept" Trial. A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy.

9 May 2014

Study: Pravastatin slows down growth of kidney cysts in children, young adults with ADPKD

Results from a study by University of Colorado School of Medicine researchers show that pravastatin, a medicine widely used for treatment of high cholesterol, also slows down the growth of kidney cysts in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).

9 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance, Inc. today announced complete results from its phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (attention deficit hyperactivity disorder).

8 May 2014

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.

8 May 2014

Research may have "major implications" for treatment of urinary tract infections in children

A major new pediatric research study led by a Wayne State University researcher, funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) and published this week in the New England Journal of Medicine (NEJM), has "major implications" for the treatment of urinary tract infections (UTIs) in millions of American children.

8 May 2014

Ambrisentan cleared for use with phenprocoumon

Starting treatment with ambrisentan does not necessitate adjusting the dose of the oral anticoagulant phenprocoumon in patients with pulmonary hypertension who require both medications, report researchers.

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.

6 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor.

6 May 2014

New phase III clinical trial shows non-invasive focused ultrasound treatment relieves cancer pain

When cancer progresses and spreads to the bone, patients often suffer debilitating pain. Now, a new phase III clinical trial shows that non-invasive magnetic resonance guided focused ultrasound treatment that heats the cancer within the bone, relieves pain and improves function for most patients when other treatment options are limited.

6 May 2014

Extremely premature babies should not be given drug to prevent fatal fungal infection

In most circumstances, extremely premature babies should not be given a drug to prevent a potentially fatal fungal infection, according to findings by a Duke Medicine-led research team.

5 May 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from the Phase 3 ADVANCE clinical trial for peginterferon beta-1a in adults with relapsing forms of multiple sclerosis (RMS) has been presented at the 66th American Academy of Neurology (AAN) annual meeting.

5 May 2014

High-dose steroid therapy following surgery do not improve bile drainage among infants

Among infants who underwent surgery to repair bile ducts that do not drain properly (biliary atresia), the administration of high-dose steroid therapy following surgery did not significantly improve bile drainage after 6 months, although a small clinical benefit could not be excluded, according to a study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

High doses of steroids fail to improve outcomes in pediatric liver disease

A multi-center study concludes that treating infants with high doses of steroids fails to improve medical outcomes in the end-stage pediatric liver disease biliary atresia and leads to earlier onset of serious adverse events.

5 May 2014

Research provides definitive evidence of safety of Tdap immunization during pregnancy

A preliminary study finds that receipt of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in the third trimester of pregnancy did not increase the risk of adverse events for the mother or infant, according to a study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

Prenatal DHA supplementation does not improve cognitive outcomes in children

Although there are recommendations for pregnant women to increase their intake of the omega-3 fatty acid docosahexaenoic acid (DHA) to improve fetal brain development, a randomized trial finds that prenatal DHA supplementation did not result in improved cognitive, problem-solving or language abilities for children at four years of age, according to the study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

Placebo News and Research

FLUIDDA's breakthrough imaging technology helps optimize COPD treatment

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Patients with Parkinson's disease show improvements after exenatide therapy

Study: Pravastatin slows down growth of kidney cysts in children, young adults with ADPKD

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Research may have "major implications" for treatment of urinary tract infections in children

Ambrisentan cleared for use with phenprocoumon

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Naurex's two lead antidepressant programs achieve major milestones

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

New phase III clinical trial shows non-invasive focused ultrasound treatment relieves cancer pain

Extremely premature babies should not be given drug to prevent fatal fungal infection

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

High-dose steroid therapy following surgery do not improve bile drainage among infants

High doses of steroids fail to improve outcomes in pediatric liver disease

Research provides definitive evidence of safety of Tdap immunization during pregnancy

Prenatal DHA supplementation does not improve cognitive outcomes in children

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News